Digital Twins Help Bioreactors to Produce Personalized, Cell-Based Therapies
While a few big pharma companies produced amazing results in developing and manufacturing massive amounts of COVID-19 vaccines in under a year, many pharma challenges exist on a smaller scale — that of an individual patient or small group of patients with a rare disease. This “personalized medicine” approach has led companies like Antleron in Leuven, Belgium, to redefine the concept of a bioreactor, using Ansys simulation solutions an digital twins to optimize and customize the growth of cells for therapeutic purposes.
White Paper from 
If your Download does not start Automatically, Click Download Whitepaper